Alexion Pharma (ALXN) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
UBS Reiterates Buy on Alexion Pharma (ALXN) Following 4Q EPS Beat
February 4, 2016 8:39 AM ESTUBS maintained a Buy rating on Alexion Pharmaceuticals (NASDAQ: ALXN), and cut the price target to $200.00 (from $222.00), following the company's 4Q earnings report. ALXN reported a $0.03 EPS beat, despite a $7m miss in Soliris sales, and a $4m miss in operating income, due to a beat on taxes and higher non-operating income.
Analyst... More
